198 related articles for article (PubMed ID: 25407517)
41. Pathogenetic Implications of BRAF Mutation Distribution in Stage IV Melanoma Patients.
Baiter M; Schuler G; Hartmann A; Schneider-Stock R; Heinzerling L
Dermatology; 2015; 231(2):127-33. PubMed ID: 26138035
[TBL] [Abstract][Full Text] [Related]
42. Prognostic value of BRAF(V⁶⁰⁰) mutations in melanoma patients after resection of metastatic lymph nodes.
Moreau S; Saiag P; Aegerter P; Bosset D; Longvert C; Hélias-Rodzewicz Z; Marin C; Peschaud F; Chagnon S; Zimmermann U; Clerici T; Emile JF
Ann Surg Oncol; 2012 Dec; 19(13):4314-21. PubMed ID: 22772867
[TBL] [Abstract][Full Text] [Related]
43. TERT promoter mutation subtypes and survival in stage I and II melanoma patients.
Andrés-Lencina JJ; Rachakonda S; García-Casado Z; Srinivas N; Skorokhod A; Requena C; Soriano V; Kumar R; Nagore E
Int J Cancer; 2019 Mar; 144(5):1027-1036. PubMed ID: 30070694
[TBL] [Abstract][Full Text] [Related]
44. Immunohistochemistry is highly sensitive and specific for the detection of V600E BRAF mutation in melanoma.
Long GV; Wilmott JS; Capper D; Preusser M; Zhang YE; Thompson JF; Kefford RF; von Deimling A; Scolyer RA
Am J Surg Pathol; 2013 Jan; 37(1):61-5. PubMed ID: 23026937
[TBL] [Abstract][Full Text] [Related]
45. TERT promoter mutation status as an independent prognostic factor in cutaneous melanoma.
Griewank KG; Murali R; Puig-Butille JA; Schilling B; Livingstone E; Potrony M; Carrera C; Schimming T; Möller I; Schwamborn M; Sucker A; Hillen U; Badenas C; Malvehy J; Zimmer L; Scherag A; Puig S; Schadendorf D
J Natl Cancer Inst; 2014 Sep; 106(9):. PubMed ID: 25217772
[TBL] [Abstract][Full Text] [Related]
46. Conjunctival melanomas harbor BRAF and NRAS mutations and copy number changes similar to cutaneous and mucosal melanomas.
Griewank KG; Westekemper H; Murali R; Mach M; Schilling B; Wiesner T; Schimming T; Livingstone E; Sucker A; Grabellus F; Metz C; Süsskind D; Hillen U; Speicher MR; Woodman SE; Steuhl KP; Schadendorf D
Clin Cancer Res; 2013 Jun; 19(12):3143-52. PubMed ID: 23633454
[TBL] [Abstract][Full Text] [Related]
47. NRAS (Q61R), BRAF (V600E) immunohistochemistry: a concomitant tool for mutation screening in melanomas.
Uguen A; Talagas M; Costa S; Samaison L; Paule L; Alavi Z; De Braekeleer M; Le Marechal C; Marcorelles P
Diagn Pathol; 2015 Jul; 10():121. PubMed ID: 26204954
[TBL] [Abstract][Full Text] [Related]
48. Younger age at the time of first metastasis in BRAF-mutated compared to BRAF wild-type melanoma patients.
Saint-Jean M; Quereux G; Nguyen JM; Peuvrel L; Brocard A; Vallee A; Knol AC; Khammari A; Denis MG; Dréno B
Oncol Rep; 2014 Aug; 32(2):808-14. PubMed ID: 24926836
[TBL] [Abstract][Full Text] [Related]
49. BRAF and c-kit gene copy number in mutation-positive malignant melanoma.
Willmore-Payne C; Holden JA; Hirschowitz S; Layfield LJ
Hum Pathol; 2006 May; 37(5):520-7. PubMed ID: 16647948
[TBL] [Abstract][Full Text] [Related]
50. Telomerase reverse transcriptase promoter alterations across cancer types as detected by next-generation sequencing: A clinical and molecular analysis of 423 patients.
Schwaederle M; Krishnamurthy N; Daniels GA; Piccioni DE; Kesari S; Fanta PT; Schwab RB; Patel SP; Parker BA; Kurzrock R
Cancer; 2018 Mar; 124(6):1288-1296. PubMed ID: 29211306
[TBL] [Abstract][Full Text] [Related]
51. Multiplex ligation-dependent probe amplification of conjunctival melanoma reveals common BRAF V600E gene mutation and gene copy number changes.
Lake SL; Jmor F; Dopierala J; Taktak AF; Coupland SE; Damato BE
Invest Ophthalmol Vis Sci; 2011 Jul; 52(8):5598-604. PubMed ID: 21693616
[TBL] [Abstract][Full Text] [Related]
52. Clinical outcome and pathological features associated with NRAS mutation in cutaneous melanoma.
Devitt B; Liu W; Salemi R; Wolfe R; Kelly J; Tzen CY; Dobrovic A; McArthur G
Pigment Cell Melanoma Res; 2011 Aug; 24(4):666-72. PubMed ID: 21615881
[TBL] [Abstract][Full Text] [Related]
53. BRAF inhibitor therapy-associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression.
Mudaliar K; Tetzlaff MT; Duvic M; Ciurea A; Hymes S; Milton DR; Tsai KY; Prieto VG; Torres-Cabala CA; Curry JL
Hum Pathol; 2016 Apr; 50():79-89. PubMed ID: 26997441
[TBL] [Abstract][Full Text] [Related]
54. Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy.
Casula M; Colombino M; Satta MP; Cossu A; Lissia A; Budroni M; Simeone E; Calemma R; Loddo C; Caracò C; Mozzillo N; Daponte A; Comella G; Canzanella S; Guida M; Castello G; Ascierto PA; Palmieri G;
Eur J Cancer; 2007 Jan; 43(1):137-43. PubMed ID: 17055252
[TBL] [Abstract][Full Text] [Related]
55. Comparison of 2 monoclonal antibodies for immunohistochemical detection of BRAF V600E mutation in malignant melanoma, pulmonary carcinoma, gastrointestinal carcinoma, thyroid carcinoma, and gliomas.
Routhier CA; Mochel MC; Lynch K; Dias-Santagata D; Louis DN; Hoang MP
Hum Pathol; 2013 Nov; 44(11):2563-70. PubMed ID: 24071017
[TBL] [Abstract][Full Text] [Related]
56. Mutant V600E BRAF increases hypoxia inducible factor-1alpha expression in melanoma.
Kumar SM; Yu H; Edwards R; Chen L; Kazianis S; Brafford P; Acs G; Herlyn M; Xu X
Cancer Res; 2007 Apr; 67(7):3177-84. PubMed ID: 17409425
[TBL] [Abstract][Full Text] [Related]
57. BRAF mutation status is an independent prognostic factor for resected stage IIIB and IIIC melanoma: implications for melanoma staging and adjuvant therapy.
Barbour AP; Tang YH; Armour N; Dutton-Regester K; Krause L; Loffler KA; Lambie D; Burmeister B; Thomas J; Smithers BM; Hayward NK
Eur J Cancer; 2014 Oct; 50(15):2668-76. PubMed ID: 25070294
[TBL] [Abstract][Full Text] [Related]
58. Concordant BRAFV600E mutation status in primary melanomas and associated naevi: implications for mutation testing of primary melanomas.
Kakavand H; Crainic O; Lum T; O'Toole SA; Kefford RF; Thompson JF; Wilmott JS; Long GV; Scolyer RA
Pathology; 2014 Apr; 46(3):193-8. PubMed ID: 24614711
[TBL] [Abstract][Full Text] [Related]
59. BRAF wild-type melanoma in situ arising in a BRAF V600E mutant dysplastic nevus.
Tan JM; Lin LL; Lambie D; Flewell-Smith R; Jagirdar K; Schaider H; Sturm RA; Prow TW; Soyer HP
JAMA Dermatol; 2015 Apr; 151(4):417-21. PubMed ID: 25607474
[TBL] [Abstract][Full Text] [Related]
60. Quantification of BRAF V600E alleles predicts papillary thyroid cancer progression.
Kim MH; Bae JS; Lim DJ; Lee H; Jeon SR; Park GS; Jung CK
Endocr Relat Cancer; 2014; 21(6):891-902. PubMed ID: 25266729
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
